Citius Pharmaceuticals (NASDAQ:CTXR) Shares Up 13.7%

Citius Pharmaceuticals, Inc. (NASDAQ:CTXRGet Free Report)’s share price shot up 13.7% during trading on Monday . The company traded as high as $0.62 and last traded at $0.60. 2,654,748 shares were traded during trading, an increase of 104% from the average session volume of 1,301,384 shares. The stock had previously closed at $0.53.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price target on shares of Citius Pharmaceuticals in a research note on Friday, May 31st.

Get Our Latest Stock Report on CTXR

Citius Pharmaceuticals Stock Up 10.3 %

The firm has a 50 day moving average price of $0.64 and a 200 day moving average price of $0.72. The stock has a market cap of $134.74 million, a P/E ratio of -3.11 and a beta of 1.68.

Citius Pharmaceuticals (NASDAQ:CTXRGet Free Report) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. Equities analysts predict that Citius Pharmaceuticals, Inc. will post -0.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Citius Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in CTXR. BNP Paribas Financial Markets increased its position in Citius Pharmaceuticals by 88.5% in the 1st quarter. BNP Paribas Financial Markets now owns 69,615 shares of the company’s stock valued at $62,000 after acquiring an additional 32,686 shares during the period. Wealth Advisory Solutions LLC acquired a new stake in Citius Pharmaceuticals in the 1st quarter valued at $135,000. Finally, Vanguard Group Inc. lifted its position in shares of Citius Pharmaceuticals by 1.5% during the first quarter. Vanguard Group Inc. now owns 7,005,119 shares of the company’s stock worth $6,286,000 after purchasing an additional 104,889 shares during the last quarter. Institutional investors and hedge funds own 16.88% of the company’s stock.

About Citius Pharmaceuticals

(Get Free Report)

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.

Recommended Stories

Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with's FREE daily email newsletter.